Beyondspring Inc Stock Price, News & Analysis

BeyondSpring (NASDAQ: BYSI) announced the dosing of the first patient in a Phase 1b/2 trial studying plinabulin in combination with PD-1/PD-L1 inhibitors and radiation therapy for advanced cancers, including non-small cell lung cancer (NSCLC). This triple therapy could address resistance to immunotherapy, a significant unmet medical need. The study, led by Dr. Vivek Subbiah at MD Anderson Cancer Center, aims to evaluate safety and tolerability in patients who have progressed on prior treatments. Plinabulin has shown promise in overcoming resistance, with a notable 43% response rate in previous studies.

BeyondSpring announced that the FDA has accepted its New Drug Application (NDA) for plinabulin in combination with G-CSF for preventing chemotherapy-induced neutropenia (CIN), granting it Priority Review with a target action date of November 30, 2021. This combination aims to improve CIN prevention, addressing a significant medical need that affects up to 467,500 cancer patients annually. The NDA submission included pivotal Phase 3 data showing notable benefits over existing treatments, such as a 31.5% rate of preventing grade 4 neutropenia. The combination also demonstrated a reduction in severe adverse events and improved patient quality of life.

BeyondSpring is scheduled to present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 9:00 am ET. Interested parties can access the presentation through a live webcast. BeyondSpring focuses on developing innovative cancer therapies, with their lead asset, plinabulin, aimed at preventing chemotherapy-induced neutropenia and enhancing cancer treatment outcomes. A replay of the presentation will be available post-event on their investor relations page.

BeyondSpring announced positive preliminary results from a Phase 1 trial of plinabulin combined with nivolumab and ipilimumab for treating small cell lung cancer (SCLC). The study showed a favorable 46% objective response rate (ORR) among 13 evaluable patients with resistant tumors. The combination also re-sensitized tumors previously treated with PD-1/PD-L1 inhibitors, achieving a 43% ORR.

The trial highlighted the treatment's safety with no Grade 4 events reported, and only 12.5% experiencing Grade 3/4 immune-related adverse events (IR-AEs), signaling potential for further development.

BeyondSpring Inc. (NASDAQ: BYSI) announced that CEO Dr. Lan Huang will present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13, 2021, at 8:00 am ET. The event will include opportunities for 1x1 meetings. The presentation can be accessed via webcast and will be available for replay on BeyondSpring's investor section afterward. BeyondSpring focuses on innovative cancer therapies, with its lead asset, plinabulin, in pivotal studies for cancer treatment and prevention of chemotherapy-induced neutropenia in the U.S. and China.

BeyondSpring, a biopharmaceutical company, filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the SEC on April 30, 2021. The report includes audited financial statements and is accessible via the SEC's website and BeyondSpring's site under the Investors section. BeyondSpring focuses on developing innovative cancer therapies, primarily its lead asset plinabulin, aimed at preventing chemotherapy-induced neutropenia and studying its effects in non-small cell lung cancer. Shareholders can request a hard copy of the report free of charge.

BeyondSpring, a biopharmaceutical company focused on innovative cancer therapies, reported its 2020 financial results and recent milestones. The company completed NDAs for plinabulin in the U.S. and China for preventing chemotherapy-induced neutropenia, leveraging positive Phase 3 trial data. BeyondSpring secured $86.3 million in equity financing, ending 2020 with $109.5 million in cash. R&D expenses rose to $41.8 million while G&A expenses increased to $22.6 million, leading to a net loss of $61 million. Positive Phase 3 survival data for NSCLC is anticipated in mid-2021.

BeyondSpring (NASDAQ: BYSI) has announced five key presentations at the ASCO Annual Meeting, focusing on plinabulin, its lead cancer therapy. The presentations will highlight clinically significant improvements, including the reduction of febrile neutropenia and hospitalization rates in patients undergoing chemotherapy. Notably, plinabulin's combination with checkpoint inhibitors targeting small cell lung cancer will also be discussed. BeyondSpring aims to demonstrate plinabulin's unique capabilities in enhancing patient outcomes as it seeks to bring the drug to market in 2022.

BeyondSpring Inc. (NASDAQ: BYSI) will report its financial results for the year and quarter ending December 31, 2020, on April 30, 2021. A conference call is scheduled for 8:30 AM ET on the same day to discuss these results and provide a corporate update. BeyondSpring focuses on developing innovative cancer therapies, with its lead asset, plinabulin, aimed at preventing chemotherapy-induced neutropenia and currently under NDA review in the US and China. The company also has a pivotal study in non-small cell lung cancer and various immuno-oncology assets in its pipeline.